fda glp-1 compounding warning letters october 2025 September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

24.41

★★★★☆4.8 (126)

Week Ending October 31, 2025: Featuring a Panel of FDA Compliance Leaders Discussing Key Current Concerns

24.47

★★★★★4.9 (98)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

24.08

★★★★★5.0 (157)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

27.84

★★★★★4.7 (84)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

24.41

★★★★★4.9 (203)

Hims and Hers warns investors about potential liability for FDA-regulated compounded prescription drug ads – Partnership for Safe Medicines

25.16

★★★★★5.0 (176)

Ref 0306

28.30

★★★★★4.8 (132)